Fast DNA Vaccination Strategy Elicits a Stronger Immune Response Dependent on CD8CD11c Cell Accumulation

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Dec 24

PMID 34950581

Citations 3

Authors

Chenlu Liu

Xianling Cong

Yuqian Wang

Qianqian Guo

Yu Xie

Fei Geng

Jie Guo

Ling Dong

Yi Zhou

Hui Wu

Bin Yu

Jiaxin Wu

Haihong Zhang

Xianghui Yu

Wei Kong

Affiliations

Soon will be listed here.

Abstract

Conventional DNA vaccine strategies usually employ a regimen of immunizations at 2-week or longer intervals to induce effective memory cell-dependent immune responses. Clinical cancer treatment requires a faster immunization strategy to contend with tumor progression. In this study, a novel fast immunization strategy was established, wherein a DNA vaccine was intramuscularly administered on days 0, 2, and 5 in a murine lung cancer model. Effector cells peaked 7 to 10 days after the last vaccination. Compared with traditional 2-week-interval immunization strategies, antigen-specific cytolysis and INF-γ secretion were significantly enhanced under the fast vaccination approach. As a result, the rapidly administered DNA vaccine elicited stronger and more prompt antitumor effects. The probable underlying mechanism of fast immunization was the accumulation of CD8CD11c antigen-presenting cells at the injection site, which enhanced subsequent antigen presentation. In conclusion, the fast DNA vaccination strategy shortened vaccination time to 5 days and elicited a stronger antitumor immune response.

Citing Articles

Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines.

Lan J, Feng D, He X, Zhang Q, Zhang R Vaccines (Basel). 2024; 12(10).

PMID: 39460352 PMC: 11511158. DOI: 10.3390/vaccines12101187.

Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models.

Shi S, Zhang L, Zheng A, Xie F, Kesse S, Yang Y Cancer Immunol Immunother. 2024; 73(12):248.

PMID: 39358555 PMC: 11447239. DOI: 10.1007/s00262-024-03838-8.

Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.

Takanashi A, Pouton C, Al-Wassiti H Mol Pharm. 2023; 20(8):3876-3885.

PMID: 37491979 PMC: 10411422. DOI: 10.1021/acs.molpharmaceut.2c01024.

References

Mei Y, Zhao L, Liu Y, Gong H, Song Y, Lei L . Combining DNA Vaccine and AIDA-1 in Attenuated Activates Tumor-Specific CD4 and CD8 T-cell Responses. Cancer Immunol Res. 2017; 5(6):503-514. DOI: 10.1158/2326-6066.CIR-16-0240-T. View

Johnson L, Frye T, Arnot A, Marquette C, Couture L, Gendron-Fitzpatrick A . Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2005; 24(3):293-303. DOI: 10.1016/j.vaccine.2005.07.074. View

Tiberio L, Del Prete A, Schioppa T, Sozio F, Bosisio D, Sozzani S . Chemokine and chemotactic signals in dendritic cell migration. Cell Mol Immunol. 2018; 15(4):346-352. PMC: 6052805. DOI: 10.1038/s41423-018-0005-3. View

Ott P, Hu Z, Keskin D, Shukla S, Sun J, Bozym D . An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662):217-221. PMC: 5577644. DOI: 10.1038/nature22991. View

Rezaei T, Davoudian E, Khalili S, Amini M, Hejazi M, de la Guardia M . Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res. 2020; 34(5):869-891. DOI: 10.1111/pcmr.12933. View

Aravanis A, Lee M, Klausner R . Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. Cell. 2017; 168(4):571-574. DOI: 10.1016/j.cell.2017.01.030. View

Chen Y, Chang M, Chiang Y, Lin H, Sun N, Chen C . Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation. Cancer Lett. 2018; 425:152-163. DOI: 10.1016/j.canlet.2018.03.032. View

Sandor A, Lindsay R, Dyjack N, Whitesell J, Rios C, Bradley B . CD11c Cells Are Gatekeepers for Lymphocyte Trafficking to Infiltrated Islets During Type 1 Diabetes. Front Immunol. 2019; 10:99. PMC: 6365440. DOI: 10.3389/fimmu.2019.00099. View

Lopes A, Vanvarenberg K, Kos S, Lucas S, Colau D, Van den Eynde B . Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma. Sci Rep. 2018; 8(1):15732. PMC: 6200811. DOI: 10.1038/s41598-018-33933-7. View

10.

Du B, Waxman D . Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Lett. 2019; 470:170-180. PMC: 6956245. DOI: 10.1016/j.canlet.2019.11.025. View

11.

Guo Q, Wang L, Xu P, Geng F, Guo J, Dong L . Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. Oncoimmunology. 2020; 9(1):1841392. PMC: 7657584. DOI: 10.1080/2162402X.2020.1841392. View

12.

Chen W, Shen Y, Fan J, Zeng X, Zhang X, Luan J . IL-22-mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury. Clin Transl Med. 2021; 11(2):e324. PMC: 7901723. DOI: 10.1002/ctm2.324. View

13.

Chen W, Zai W, Fan J, Zhang X, Zeng X, Luan J . Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury. Theranostics. 2020; 10(13):5879-5894. PMC: 7254999. DOI: 10.7150/thno.43894. View

14.

Johnson L, Olson B, McNeel D . Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. J Immunother Cancer. 2017; 5(1):56. PMC: 5514519. DOI: 10.1186/s40425-017-0260-3. View

15.

Liu C, Lu Z, Xie Y, Guo Q, Geng F, Sun B . Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunol Lett. 2018; 200:33-42. DOI: 10.1016/j.imlet.2018.06.004. View

16.

Wu J, Waxman D . Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett. 2014; 353(2):272-80. PMC: 4162810. DOI: 10.1016/j.canlet.2014.07.033. View

17.

Bins A, Jorritsma A, Wolkers M, Hung C, Wu T, Schumacher T . A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med. 2005; 11(8):899-904. DOI: 10.1038/nm1264. View

18.

Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y . DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother. 2012; 61(10):1857-67. PMC: 11028718. DOI: 10.1007/s00262-012-1296-3. View

19.

Wolff J, Malone R, Williams P, Chong W, Acsadi G, Jani A . Direct gene transfer into mouse muscle in vivo. Science. 1990; 247(4949 Pt 1):1465-8. DOI: 10.1126/science.1690918. View

20.

Frankel T, Perusina Lanfranca M, Zou W . The Role of Tumor Microenvironment in Cancer Immunotherapy. Adv Exp Med Biol. 2017; 1036:51-64. DOI: 10.1007/978-3-319-67577-0_4. View